| Institution: | 1. AP-HP, Henri-Mondor Hospital, Department of Internal and Geriatric Medicine, Sud-Val-de-Marne Geriatric Oncology Unit, Créteil, France;2. AP-HP, Henri-Mondor Hospital, Departement of Drug Development, Clinical Pharmacology in Oncology, France;3. AP-HP, Henri-Mondor Hospital, Department of Pharmacy, Créteil, France;4. University Paris-Est, Paris Est Créteil University (UPEC), CEpiA (Clinical Epidemiology and Ageing), EA 7376-IMRB, Créteil, France;5. AP-HP, Henri-Mondor Hospital, Department of Public Health, Clinical Research Unit (URC-Mondor), Créteil, France;6. AP-HP, Henri-Mondor Hospital, Department of Medical Oncology, Créteil, France;7. AP-HP, Ambroise Paré Hospital, Department of Geriatrics, Boulogne-Billancourt, France;8. AP-HP, Cochin Hospital, Department of Medical Oncology, ARIANE, Paris, France;9. AP-HP, Hopital Europeen Georges Pompidou, Department of Geriatrics, Paris, France;1. Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA;2. James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA;3. Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA;4. Division of Geriatric and Palliative Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA |
